76006-07-0 Usage
Description
5-Methoxy-1H-pyrazolo[3,4-c]pyridine is a heterocyclic chemical compound with a molecular formula C8H7N3O. It features a pyrazole ring fused to a pyridine ring, with a methoxy group attached to the pyridine ring. 5-METHOXY-1H-PYRAZOLO[3,4-C]PYRIDINE is known for its unique structure and functional groups, making it a valuable intermediate in the synthesis of biologically active molecules.
Uses
Used in Medicinal Chemistry and Pharmaceutical Research:
5-Methoxy-1H-pyrazolo[3,4-c]pyridine is used as a building block for the synthesis of various biologically active molecules, particularly in the development of potential drugs targeting the central nervous system. Its unique structure and functional groups contribute to its value in creating potential therapeutic agents.
Used in Agrochemicals:
5-Methoxy-1H-pyrazolo[3,4-c]pyridine may also have applications in the agrochemical industry, where its unique structure and functional groups can be utilized in the development of new agrochemical products.
Used in Materials Science:
Additionally, 5-Methoxy-1H-pyrazolo[3,4-c]pyridine may find use in materials science, where its properties can be explored for the development of new materials with specific characteristics and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 76006-07-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,0,0 and 6 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 76006-07:
(7*7)+(6*6)+(5*0)+(4*0)+(3*6)+(2*0)+(1*7)=110
110 % 10 = 0
So 76006-07-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3O/c1-11-7-2-5-3-9-10-6(5)4-8-7/h2-4H,1H3,(H,9,10)
76006-07-0Relevant articles and documents
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00633, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.